Overview

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Status:
Recruiting

Trial end date:
2029-12-30

Target enrollment:

Participant gender:

Summary

The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo, Inc.

Treatments:

Pertuzumab
Taxane
Trastuzumab